Citi Out Positive on Coherus Biosciences (CHRS): 'Erasing the $230M convert debt due in 2026 extinguishes a much-debated overhang'
Tweet Send to a Friend
Citi analyst Yigal Nochomovitz reiterated a Buy rating and $8.00 price target on Coherus Biosciences (NASDAQ: CHRS).The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
